Form 4: Akebia Therapeutics Director Myles Wolf Granted Significant Equity Awards

Akebia Therapeutics, Inc. Director Myles Wolf was granted 35,700 restricted stock units and options to purchase 53,600 shares of common stock as part of the company's non-employee director compensation program.

Summary

• Akebia Therapeutics, Inc. (AKBA) Director Myles Wolf received equity awards on June 10, 2025.
• The awards include 35,700 shares of Common Stock in the form of Restricted Stock Units (RSUs), granted at a price of $0.00.
• The awards also include options to purchase 53,600 shares of Common Stock, with an exercise price of $3.92 per share.
• Both the RSUs and Stock Options will vest 100% on the first anniversary of the grant date (June 10, 2026) or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the grant date, subject to Mr. Wolf's continued service to the Issuer.
• The Stock Options will become exercisable on June 10, 2026, and have an expiration date of June 10, 2035.
• These grants were made pursuant to the Issuer's 2023 Stock Incentive Plan and the Fourth Amended and Restated Non-Employee Director Compensation Program.
• Following these transactions, Myles Wolf beneficially owns 133,381 shares of Common Stock and 53,600 Stock Options.

Sentiment

Score: 7

Explanation: This Form 4 reports a routine equity compensation grant to a director, which is a positive for aligning interests but does not provide new operational or financial performance data that would significantly alter the company's outlook.

Positives

• The grant of equity awards to a director aligns his financial interests with those of the shareholders, incentivizing long-term value creation.
• The awards are part of a pre-established compensation program, indicating a structured and transparent approach to director remuneration.

Risks

• The vesting of both the Restricted Stock Units and Stock Options is subject to the Reporting Person's continued service to the Issuer, meaning the awards could be forfeited if the director ceases service before the vesting date.

Future Outlook

The vesting schedule for the equity awards extends into the future, indicating a continued alignment of the director's interests with the company's long-term performance and strategic objectives.

Industry Context

The grant of equity awards to non-employee directors is a standard compensation practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors. This practice aims to align the interests of the board members with the long-term performance and shareholder value creation of the company.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as components of non-employee director compensation is a common and widely accepted practice in the U.S. public markets, including the biotech industry.
• The vesting schedule tied to continued service is typical for such awards, ensuring ongoing commitment.
• While specific comparable companies are not named in the filing, the structure of this compensation package is consistent with general industry benchmarks for director remuneration in companies of similar size and stage of development.

Corporate Governance

Related Party Transactions

• The grant of equity awards to Myles Wolf, a director of Akebia Therapeutics, Inc., constitutes a related party transaction, which is a standard form of compensation for non-employee directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial incentives with the long-term interests of shareholders, as the value of the awards is tied to the company's stock performance.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• Vesting of the 35,700 Restricted Stock Units on June 10, 2026, or earlier, immediately prior to the first annual meeting of stockholders after the grant date.
• Vesting and exercisability of the 53,600 Stock Options on June 10, 2026, or earlier, immediately prior to the first annual meeting of stockholders after the grant date.
• Potential exercise of the Stock Options by Myles Wolf after they become exercisable and before their expiration on June 10, 2035.

Key Dates

Keywords

Akebia Therapeutics, AKBA, Myles Wolf, SEC Form 4, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Insider Ownership, Corporate Governance